Pediatric Pharmacogenomics

  • Ning Wang
  • Dennis Drotar
  • Gurjit K. Khurana Hershey
Part of the Issues in Clinical Child Psychology book series (ICCP)


Over the past several decades, one of the most fascinating achievements is the completion of the first draft of the human genome followed by subsequent creation of the map of human genetic variation. With these accomplishments in the human genetics field, scientists now have a better understanding on human diversity at the molecular level. It has long been known that the responses to many commonly used drugs vary greatly among patients. For example, when the same dose of the same drug is prescribed to a group of patients diagnosed with the same disease, some may respond to the treatment as expected, some may have no therapeutic response, whereas others may suffer clinically toxic or even fatal adverse effects.


Acute Lymphoblastic Leukemia Drug Response Variable Number Tandem Repeat Asthma Treatment Pharmacogenetic Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aiuti, A. (2002). Advances in gene therapy for ADA-deficient SCID. Current Opinion in Molecular Therapeutics, 4, 515–522.PubMedGoogle Scholar
  2. Asghari, V., Sanyal, S., Buchwaldt, S., Paterson, A., Jovanovic, V., & Van Tol, H. H. (1995). Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. Journal of Neurochemistry, 65, 1157–1165.PubMedCrossRefGoogle Scholar
  3. Barnes, P. J. (1995). Inhaled glucocorticoids for asthma. New England Journal of Medicine, 332, 868–875.PubMedCrossRefGoogle Scholar
  4. Bauman, L. J., Wright, E., Leickly, F. E., Crain, E., Kruszon-Moran, D., Wade, S. L., et al. (2002). Relationship of adherence to pediatric asthma morbidity among inner-city children. Pediatrics, 110, e6.PubMedCrossRefGoogle Scholar
  5. Bertilsson, L., Dahl, M. L., Dalen, P., & Al-Shurbaji, A. (2002). Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. British Journal of Clinical Pharmacology, 53, 111–122.PubMedCrossRefGoogle Scholar
  6. Bertilsson, L., Dahl, M. L., & Tybring, G. (1997). Pharmacogenetics of antidepressants: Clinical aspects. Acta Psychiatrica Scandinavica Supplementum, 391, 14–21.PubMedCrossRefGoogle Scholar
  7. Binder, E. B., & Holsboer, F. (2006). Pharmacogenomics and antidepressant drugs. Annals of Medicine, 38, 82–94.PubMedCrossRefGoogle Scholar
  8. Boat, T. F. (2007). The future of pediatric research. Journal of Pediatrics, 151, S21–S27.PubMedCrossRefGoogle Scholar
  9. Bordignon, C., Notarangelo, L. D., Nobili, N., Ferrari, G., Casorati, G., Panina, P., et al. (1995). Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science, 270, 470–475.PubMedCrossRefGoogle Scholar
  10. Busse, W., Banks-Schlegel, S., Noel, P., Ortega, H., Taggart, V., & Elias., J. (2004). Future research directions in asthma: An NHLBI Working Group report. American Journal of Respiratory and Critical Care Medicine, 170, 683–690.PubMedCrossRefGoogle Scholar
  11. Camitta, B. M., Pullen, J., & Murphy, S. (1997). Biology and treatment of acute lymphocytic leukemia in children. Seminars in Oncology, 24, 83–91.PubMedGoogle Scholar
  12. Caraco, Y. (2004). Genes and the response to drugs. New England Journal of Medicine, 351, 2867–2869.PubMedCrossRefGoogle Scholar
  13. Caron, M. G. (1996). Images in neuroscience. A mouse knockout. American Journal of Psychiatry, 153, 1387.PubMedGoogle Scholar
  14. Chamberlain, J. S. (2002). Gene therapy of muscular dystrophy. Human Molecular Genetics, 11, 2355–2362.PubMedCrossRefGoogle Scholar
  15. Chessells, J. M., Bailey, C., & Richards, S. M. (1995). Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet, 345, 143–148.PubMedCrossRefGoogle Scholar
  16. Childhood Asthma Management Program Research Group. (1999). The Childhood Asthma Management Program (CAMP): Design, rationale, and methods. Controlled Clinical Trials, 20, 91–120.CrossRefGoogle Scholar
  17. Cohen, S. N., & Weber, W. W. (1972). Pharmacogenetics. Pediatric Clinics of North America, 19, 21–36.PubMedGoogle Scholar
  18. Conn, K. M., Halterman, J. S., Fisher, S. G., Yoos, H. L., Chin, N. P., & Szilagyi, P. G. (2005). Parental beliefs about medications and medication adherence among urban children with asthma. Ambulatory Pediatrics, 5, 306–310.PubMedCrossRefGoogle Scholar
  19. Cotrim, A. P., & Baum, B. J. (2008). Gene therapy: Some history, applications, problems, and prospects. Toxicology and Pathology, 36, 97–103.CrossRefGoogle Scholar
  20. Dales, R. E., Spitzer, W. O., Tousignant, P., Schechter, M., & Suissa, S. (1988). Clinical interpretation of airway response to a bronchodilator. Epidemiologic considerations. American Review of Respiratory Disorders, 138, 317–320.Google Scholar
  21. Dautzenberg, F. M., & Hauger, R. L. (2002). The CRF peptide family and their receptors: Yet more partners discovered. Trends in Pharmacological Sciences, 23, 71–77.PubMedCrossRefGoogle Scholar
  22. Drazen, J. M., Silverman, E. K., & Lee, T. H. (2000). Heterogeneity of therapeutic responses in asthma. British Medical Bulletin, 56, 1054–1070.PubMedCrossRefGoogle Scholar
  23. Drazen, J. M., Yandava, C. N., Dube, L., Szczerback, N., Hippensteel, R., Pillari, A., et al. (1999). Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genetics, 22, 168–170.PubMedCrossRefGoogle Scholar
  24. Drolet, G., & Rivest, S. (2001). Corticotropin-releasing hormone and its receptors: An evaluation at the transcription level in vivo. Peptides, 22, 761–767.PubMedCrossRefGoogle Scholar
  25. Drotar, D. (2000). Promoting adherence to treatment in childhood chronic illnesses: Concepts, methods, and interventions. Mahwah, NJ: Lawrence Erlbaum Associates.Google Scholar
  26. Drysdale, C. M., McGraw, D. W., Stack, C. B., Stephens, J. C., Judson, R. S., Nandabalan, K., et al. (2000). Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proceeding if the National Academy of Science USA, 97, 10483–10488.CrossRefGoogle Scholar
  27. Duffy, M. J. (2005). Predictive markers in breast and other cancers: A review. Clinical Chemotherapy, 51, 494–503.CrossRefGoogle Scholar
  28. Evans, W. E., Horner, M., Chu, Y. Q., Kalwinsky, D., & Roberts, W. M. (1991). Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. Journal of Pediatrics, 119, 985–989.PubMedCrossRefGoogle Scholar
  29. Fewell, J. G. (2008). Factor IX gene therapy for hemophilia. Methods in Molecular Biology, 423, 375–382.PubMedCrossRefGoogle Scholar
  30. Flowers, C. R., & Veenstra, D. (2004). The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics, 22, 481–493.PubMedCrossRefGoogle Scholar
  31. Froehlich, T. E., McGough, J. J., & Stein, M. A. (in press). Progress and promise of ADHD pharmacogenetics. CNS Drugs, 24(2), 99–117.Google Scholar
  32. Gillis, J. J., Gilger, J. W., Pennington, B. F., & DeFries, J. C. (1992). Attention deficit disorder in reading-disabled twins: Evidence for a genetic etiology. Journal of Abnormal Child Psychology, 20, 303–315.PubMedCrossRefGoogle Scholar
  33. Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., & Caron, M. G. (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature, 379, 606–612.PubMedCrossRefGoogle Scholar
  34. Glauser, T. A. (2007). Monitoring gene changes during antiepileptic drug therapy to widen the safety window and reduce pharmacoresistance. Epilepsia, 48(Suppl 1), 19–25.PubMedCrossRefGoogle Scholar
  35. Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., et al. (1988). Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 331, 442–446.PubMedCrossRefGoogle Scholar
  36. Hamarman, S., Fossella, J., Ulger, C., Brimacombe, M., & Dermody, J. (2004). Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: A pharmacogenetic study. Journal of Child and Adolescent Psychopharmacology, 14, 564–574.PubMedCrossRefGoogle Scholar
  37. Hartigan-O’Connor, D., & Chamberlain, J. S. (2000). Developments in gene therapy for muscular dystrophy. Microscopy Research and Technique, 48, 223–238.PubMedCrossRefGoogle Scholar
  38. Hortelano, G., & Chang, P. L. (2000). Gene therapy for hemophilia. Artificial Cells, Blood Substitutes and Immobilization Biotechnology, 28, 1–24.CrossRefGoogle Scholar
  39. Husain, A., Loehle, J. A., & Hein, D. W. (2007). Clinical pharmacogenetics in pediatric patients. Pharmacogenomics, 8, 1403–1411.PubMedCrossRefGoogle Scholar
  40. Kahana, S., Drotar, D., & Frazier, T. (2008). Meta-analysis of psychological interventions to promote adherence to treatment in pediatric chronic health conditions. Journal of Pediatric Psychology, 33, 590–611.PubMedCrossRefGoogle Scholar
  41. Kanbayashi, Y., Nakata, Y., Fujii, K., Kita, M., & Wada, K. (1994). ADHD-related behavior among non-referred children: Parents’ ratings of DSM-III-R symptoms. Child Psychiatry and Human Development, 25, 13–29.PubMedCrossRefGoogle Scholar
  42. Keller, M. B., & Lowenstein, S. R. (2002). Epidemiology of asthma. Seminars in Respiratory and Critical Care Medicine, 23, 317–329.PubMedCrossRefGoogle Scholar
  43. Kenna, L. A., Labbe, L., Barrett, J. S., & Pfister, M. (2005). Modeling and simulation of adherence: Approaches and applications in therapeutics. AAPS Journal, 7, E390–E407.PubMedCrossRefGoogle Scholar
  44. Kirley, A., Lowe, N., Hawi, Z., Mullins, C., Daly, G., Waldman, I., et al. (2003). Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics, 121, 50–54.Google Scholar
  45. Krajinovic, M., Labuda, D., Mathonnet, G., Labuda, M., Moghrabi, A., Champagne, J., et al. (2002). Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clinical Cancer Research, 8, 802–810.PubMedGoogle Scholar
  46. Krynetski, E. Y., & Evans, W. E. (1998). Pharmacogenetics of cancer therapy: Getting personal. American Journal of Human Genetics, 63, 11–16.PubMedCrossRefGoogle Scholar
  47. Krynetskiy, E., & McDonnell, P. (2007). Building individualized medicine: Prevention of adverse reactions to warfarin therapy. Journal of Pharmacology and Experimental Therapeutics, 322, 427–434.PubMedCrossRefGoogle Scholar
  48. Langley, K., Turic, D., Peirce, T. R., Mills, S., Van Den Bree, M. B., Owen, M. J., et al. (2005). No support for association between the dopamine transporter (DAT1) gene and ADHD. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics, 139, 7–10.CrossRefGoogle Scholar
  49. Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA, 279, 1200–1205.PubMedCrossRefGoogle Scholar
  50. Leeder, J. S., & Kearns, G. L. (2002). The challenges of delivering pharmacogenomics into clinical pediatrics. Pharmacogenomics Journal, 2, 141–143.PubMedCrossRefGoogle Scholar
  51. Lemanske, R. F., Jr., & Busse, W. W. (1997). Asthma. JAMA, 278, 1855–1873.PubMedCrossRefGoogle Scholar
  52. Lennard, L., Lilleyman, J. S., Van Loon, J., & Weinshilboum, R. M. (1990). Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet, 336, 225–229.PubMedCrossRefGoogle Scholar
  53. Lipshultz, S. E. (2005). Realizing optimal care for children with cardiovascular disease: Funding challenges and research approaches. Progress in Pediatric Cardiology, 20, 71–90.CrossRefGoogle Scholar
  54. Makoul, G., & Clayman, M. L. (2006). An integrative model of shared decision making in medical encounters. Patient Education and Counseling, 60, 301–312.PubMedCrossRefGoogle Scholar
  55. Martinez, F. D., Graves, P. E., Baldini, M., Solomon, S., & Erickson, R. (1997). Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. Journal of Clinical Investigation, 100, 3184–3188.PubMedCrossRefGoogle Scholar
  56. Masoli, M., Fabian, D., Holt, S., & Beasley, R. (2004). The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy, 59, 469–478.PubMedCrossRefGoogle Scholar
  57. McGough, J. J. (2005). Attention-deficit/hyperactivity disorder pharmacogenomics. Biological Psychiatry, 57, 1367–1373.PubMedCrossRefGoogle Scholar
  58. Meyer, U. A. (2004). Pharmacogenetics –five decades of therapeutic lessons from genetic diversity. Nature Reviews Genetics, 5, 669–676.PubMedCrossRefGoogle Scholar
  59. Meyer, U. A., & Zanger, U. M. (1997). Molecular mechanisms of genetic polymorphisms of drug metabolism. Annual Review of Pharmacology and Toxicology, 37, 269–296.PubMedCrossRefGoogle Scholar
  60. Miller, S. M., McDaniel, S. H., Rolland, J. S., & Feetham, S. L. (2006). Individuals, families, and the new era of genetics: Biopsychosocial perspectives. New York: W.W. Norton & Company.Google Scholar
  61. Nakano, I. (2008). A clinical research of AADC gene therapy for Parkinson’s disease. Nippon Ronen Igakkai Zasshi, 45, 9–13.PubMedGoogle Scholar
  62. Ndegwa, S. (2007). Pharmacogenomics and warfarin therapy. Issues in Emerging Health Technologies, 7, 1–8.Google Scholar
  63. O’Neil, W. M., Gilfix, B. M., DiGirolamo, A., Tsoukas, C. M., & Wainer, I. W. (1997). N-acetylation among HIV-positive patients and patients with AIDS: When is fast, fast and slow, slow? Clinical Pharmacology and Therapeutics, 62, 261–271.PubMedCrossRefGoogle Scholar
  64. Palermo, T. M., Long, A. C., Lewandowski, A. S., Drotar, D., Quittner, A. L., & Walker, L. S. (2008). Evidence-based assessment of health-related quality of life and functional impairment in pediatric psychology. Journal of Pediatric Psychology, 33, 983–996, discussion 997–998.PubMedCrossRefGoogle Scholar
  65. Patenaude, A. F. (2005). Genetic testing for cancer: Psychological approaches for helping patients and families. Washington, DC: American Psychological Association.CrossRefGoogle Scholar
  66. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadee, W. (2001). Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA, 286, 2270–2279.PubMedCrossRefGoogle Scholar
  67. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., et al. (2004). Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ, 329, 15–19.PubMedCrossRefGoogle Scholar
  68. Polanczyk, G., Zeni, C., Genro, J. P., Guimaraes, A. P., Roman, T., Hutz, M. H., et al. (2007). Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 64, 218–224.PubMedCrossRefGoogle Scholar
  69. Pui, C. H. (2000). Acute lymphoblastic leukemia in children. Current Opinions in Oncology, 12, 3–12.CrossRefGoogle Scholar
  70. Rapoff, M. A. (1999). Adherence to pediatric medical regimens. New York: Kluwer Academic/Plenum Publishers.Google Scholar
  71. Reynolds, K. K., Valdes, R., Jr., Hartung, B. R., & Linder, M. W. (2007). Individualizing warfarin therapy. Personalized Medicine, 4, 11–31.CrossRefGoogle Scholar
  72. Riekert, K. A., & Drotar, D. (2002). The Beliefs About Medication Scale: Development, reliably, and validity. Journal of Clinical Psychology in Medical Settings, 9, 177–180.CrossRefGoogle Scholar
  73. Roman, T., Szobot, C., Martins, S., Biederman, J., Rohde, L. A., & Hutz, M. H. (2002). Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics, 12, 497–499.PubMedCrossRefGoogle Scholar
  74. Seeman, P., & Madras, B. K. (1998). Anti-hyperactivity medication: Methylphenidate and amphetamine. Molecular Psychiatry, 3, 386–396.PubMedCrossRefGoogle Scholar
  75. Shastry, B. S. (2006). Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics Journal, 6, 16–21.PubMedCrossRefGoogle Scholar
  76. Sherman, D. K., Iacono, W. G., & McGue, M. K. (1997). Attention-deficit hyperactivity disorder dimensions: A twin study of inattention and impulsivity-hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 745–753.PubMedCrossRefGoogle Scholar
  77. Sherman, D. K., McGue, M. K., & Iacono, W. G. (1997). Twin concordance for attention deficit hyperactivity disorder: A comparison of teachers’ and mothers’ reports. American Journal of Psychiatry, 154, 532–535.PubMedGoogle Scholar
  78. Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., et al. (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial. Lancet, 369, 29–36.PubMedCrossRefGoogle Scholar
  79. Spear, B. B., Heath-Chiozzi, M., & Huff, J. (2001). Clinical application of pharmacogenetics. Trends in Molecular Medicine, 7, 201–204.PubMedCrossRefGoogle Scholar
  80. Stevenson, J. (1992). Evidence for a genetic etiology in hyperactivity in children. Behavior Genetics, 22, 337–344.PubMedCrossRefGoogle Scholar
  81. Szatmari, P., Offord, D. R., & Boyle, M. H. (1989). Ontario Child Health Study: Prevalence of attention deficit disorder with hyperactivity. Journal of Child Psychology and Psychiatry, 30, 219–230.PubMedCrossRefGoogle Scholar
  82. Tantisira, K. G., Lake, S., Silverman, E. S., Palmer, L. J., Lazarus, R., Silverman, E. K., et al. (2004). Corticosteroid pharmacogenetics: Association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Human Molecular Genetics, 13, 1353–1359.PubMedCrossRefGoogle Scholar
  83. Thapar, A., Hervas, A., & McGuffin, P. (1995). Childhood hyperactivity scores are highly heritable and show sibling competition effects: Twin study evidence. Behavior Genetics, 25, 537–544.PubMedCrossRefGoogle Scholar
  84. van der Meulen, E. M., Bakker, S. C., Pauls, D. L., Oteman, N., Kruitwagen, C. L., Pearson, P. L., et al. (2005). High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sib pairs with ADHD. Journal of Child Psychology and Psychiatry, 46, 1074–1080.PubMedCrossRefGoogle Scholar
  85. Van Tol, H. H., Wu, C. M., Guan, H. C., Ohara, K., Bunzow, J. R., Civelli, O., et al. (1992). Multiple dopamine D4 receptor variants in the human population. Nature, 358, 149–152.PubMedCrossRefGoogle Scholar
  86. Venkat, V. L., Nick, T. G., Wang, Y., & Bucuvalas, J. C. (2008). An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence. Pediatric Transplant, 12, 67–72.CrossRefGoogle Scholar
  87. Vrijens, B., Gross, R., & Urquhart, J. (2005). The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analyses. Basic Clinical Pharmacology and Toxicology, 96, 225–227.CrossRefGoogle Scholar
  88. Weber, W. W. (2001). Pharmacogenetic tactics and strategies: Implications for paediatrics. Pediatric Drugs, 3, 863–881.PubMedCrossRefGoogle Scholar
  89. Weiss, S. T., Lake, S. L., Silverman, E. S., Silverman, E. K., Richter, B., Drazen, J. M., et al. (2004). Asthma steroid pharmacogenetics: A study strategy to identify replicated treatment responses. Proceedings of the American Thoracic Society, 1, 364–367.PubMedCrossRefGoogle Scholar
  90. Winsberg, B. G., & Comings, D. E. (1999). Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 1474–1477.PubMedCrossRefGoogle Scholar
  91. Wolraich, M. L., Hannah, J. N., Pinnock, T. Y., Baumgaertel, A., & Brown, J. (1996). Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 319–324.PubMedCrossRefGoogle Scholar
  92. Yang, L., Wang, Y. F., Li, J., & Faraone, S. V. (2004). Association of norepinephrine transporter gene with methylphenidate response. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 1154–1158.PubMedCrossRefGoogle Scholar
  93. Yawn, B. P., Brenneman, S. K., Allen-Ramey, F. C., Cabana, M. D., & Markson, L. E. (2006). Assessment of asthma severity and asthma control in children. Pediatrics, 118, 322–329.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Ning Wang
    • 1
  • Dennis Drotar
    • 1
  • Gurjit K. Khurana Hershey
    • 1
  1. 1.Cincinnati Children’s Hospital Medical CenterCincinnatiUSA

Personalised recommendations